Zhu Jielin, Takeh Bronhilda T, David Jummy, Sang Jordan, Moore David M, Hull Mark, Grennan Troy, Wong Jason, Montaner Julio S G, Lima Viviane D
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Laboratory for Industrial and Applied Mathematics, Department of Mathematics and Statistics, York University, Toronto, ON, Canada.
Lancet Reg Health Am. 2024 Apr 4;33:100725. doi: 10.1016/j.lana.2024.100725. eCollection 2024 May.
Men who have sex with men (MSM) in British Columbia (BC) are disproportionately affected by infectious syphilis and HIV. In this study, we developed a co-interaction model and evaluated the impact and effectiveness of possible interventions among different MSM subgroups on the syphilis epidemic.
We designed a deterministic compartmental model, which stratified MSM by HIV status and HIV pre-exposure prophylaxis (HIV-PrEP) usage into (1) HIV-negative/unaware MSM (HIV-PrEP not recommended, not on HIV-PrEP), (2) HIV-negative/unaware MSM with HIV-PrEP recommended (not on HIV-PrEP), (3) HIV-negative/unaware MSM actively on HIV-PrEP, and (4) MSM diagnosed with HIV. We estimated the effect of scaling up syphilis testing frequency from Status Quo to six-, four-, and three-months, increasing the percentage of MSM using doxycycline prevention (Doxy-P) to 25%, 50%, and 100% of the target level, and a combination of both among subgroups (2)-(4). We also assessed the impact of these interventions on the syphilis incidence rates from 2020 to 2034 in comparison to the Status Quo scenario where no intervention was introduced.
Under the Status Quo scenario, with the expansion of the HIV-PrEP program to improve syphilis testing, the syphilis incidence rate was estimated to peak at 16.1 [Credible Interval (CI):14.2-17.9] per 1,000 person-years (PYs) in 2023 and decrease to 6.7 (CI:3.8-10.9) per 1,000 PYs by 2034. The syphilis incidence rate in 2034 was estimated at 0.7 (0.3-1.3) per 1,000 PYs if MSM diagnosed with HIV could be tested every four months, and at 1.5 (0.7-3.0) per 1,000 PYs if HIV-negative/unaware MSM actively on HIV-PrEP could be tested every three months. By achieving 100% of the target coverage of Doxy-P, the syphilis incidence rate was estimated at 1.4 (0.5-3.4) if focusing on MSM diagnosed with HIV, and 2.6 (1.2-5.1) per 1,000 PYs if focusing on HIV-negative/unaware MSM actively on HIV-PrEP. Under the combined interventions, the syphilis incidence rate could be as low as 0.0 (0.0-0.1) and 0.8 (0.3-1.8) per 1,000 PYs, respectively.
The HIV-PrEP program in BC plays a crucial role in increasing syphilis testing frequency among high-risk MSM and reducing syphilis transmission among this group. In addition, introducing Doxy-P can be an effective complementary strategy to minimize syphilis incidence, especially among MSM diagnosed with HIV.
This work was funded by the Canadian Institutes of Health Research.
不列颠哥伦比亚省(BC)与男性发生性关系的男性(MSM)受感染性梅毒和艾滋病毒的影响尤为严重。在本研究中,我们建立了一个共同作用模型,并评估了不同MSM亚组中可能的干预措施对梅毒流行的影响和效果。
我们设计了一个确定性的分区模型,根据艾滋病毒状况和艾滋病毒暴露前预防(HIV-PrEP)的使用情况将MSM分为:(1)艾滋病毒阴性/未意识到感染的MSM(不推荐使用HIV-PrEP,未使用HIV-PrEP);(2)建议使用HIV-PrEP的艾滋病毒阴性/未意识到感染的MSM(未使用HIV-PrEP);(3)积极使用HIV-PrEP的艾滋病毒阴性/未意识到感染的MSM;以及(4)被诊断为艾滋病毒感染的MSM。我们估计了将梅毒检测频率从现状提高到每六个月、四个月和三个月一次的效果,将使用多西环素预防(Doxy-P)的MSM比例提高到目标水平的25%、50%和100%的效果,以及亚组(2)至(4)中两者结合的效果。我们还评估了与未采取干预措施的现状情景相比,这些干预措施对2020年至2034年梅毒发病率的影响。
在现状情景下,随着HIV-PrEP项目的扩大以改善梅毒检测,预计梅毒发病率将在2023年达到峰值,为每1000人年16.1[可信区间(CI):14.2-17.9],到2034年降至每1000人年6.7(CI:3.8-10.9)。如果每四个月对被诊断为艾滋病毒感染的MSM进行检测,预计2034年梅毒发病率为每1000人年0.7(0.3-1.3);如果每三个月对积极使用HIV-PrEP的艾滋病毒阴性/未意识到感染的MSM进行检测,预计发病率为每1000人年1.5(0.7-3.0)。如果多西环素预防(Doxy-P)的目标覆盖率达到100%,则专注于被诊断为艾滋病毒感染的MSM时,预计梅毒发病率为每1000人年1.4(0.5-3.4);专注于积极使用HIV-PrEP的艾滋病毒阴性/未意识到感染的MSM时,发病率为每1000人年2.6(1.2-5.1)。在联合干预措施下,梅毒发病率可能分别低至每1000人年0.0(0.0-0.1)和每1000人年0.8(0.3-1.8)。
BC省的HIV-PrEP项目在提高高危MSM的梅毒检测频率和减少该群体中的梅毒传播方面发挥着关键作用。此外,引入多西环素预防(Doxy-P)可以成为降低梅毒发病率的有效补充策略,特别是在被诊断为艾滋病毒感染的MSM中。
本研究由加拿大卫生研究院资助。